Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction on Friday, September 27th. The stock was sold at an average price of $46.31, for a total transaction of $1,157,750.00. Following the completion of the sale, the chief executive officer now owns 307,054 shares of the company’s stock, valued at approximately $14,219,670.74. The transaction was disclosed in a filing with the SEC, which is available through this link.
Janux Therapeutics Price Performance
NASDAQ:JANX traded down $0.37 during trading hours on Friday, hitting $46.25. The stock had a trading volume of 541,000 shares, compared to its average volume of 721,396. The company has a 50 day simple moving average of $43.92 and a two-hundred day simple moving average of $44.52. The firm has a market capitalization of $2.40 billion, a price-to-earnings ratio of -37.91 and a beta of 3.57. Janux Therapeutics, Inc. has a one year low of $5.65 and a one year high of $65.60.
Janux Therapeutics (NASDAQ:JANX – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.20. The firm had revenue of $8.90 million for the quarter, compared to analysts’ expectations of $0.77 million. Janux Therapeutics had a negative net margin of 291.17% and a negative return on equity of 8.78%. The company’s revenue for the quarter was up 709.1% on a year-over-year basis. Equities research analysts anticipate that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.
Analyst Ratings Changes
Get Our Latest Analysis on Janux Therapeutics
Institutional Trading of Janux Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in JANX. Amalgamated Bank lifted its stake in Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after purchasing an additional 368 shares during the last quarter. Summit Securities Group LLC bought a new stake in Janux Therapeutics in the second quarter worth $29,000. Plato Investment Management Ltd bought a new stake in Janux Therapeutics in the second quarter worth $42,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Janux Therapeutics in the second quarter worth $151,000. Finally, Quest Partners LLC lifted its stake in Janux Therapeutics by 307.2% in the second quarter. Quest Partners LLC now owns 5,795 shares of the company’s stock worth $243,000 after purchasing an additional 4,372 shares during the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.
About Janux Therapeutics
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Featured Articles
- Five stocks we like better than Janux Therapeutics
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Can Costco Stock Hit New Highs as Interest Rates Drop?
- Short Selling: How to Short a Stock
- These 3 Stocks Show How to Navigate Declining Consumer Confidence
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- MicroStrategy’s Returns Are 3X Higher Than Bitcoin: Time to Buy?
Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.